Overview of Dr. Ustun
Dr. Celalettin Ustun is an oncologist in Chicago, IL and is affiliated with multiple hospitals in the area, including Rush University Medical Center, M Health Fairview Southdale Hospital, and Katherine Shaw Bethea Hospital. He received his medical degree from Ankara University Faculty of Medicine and has been in practice 27 years. Dr. Ustun accepts several types of health insurance, listed below. He is one of 58 doctors at Rush University Medical Center and one of 49 doctors at M Health Fairview Southdale Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
POB
Rush University
Chicago, IL 60612
Education & Training
Medical College of GeorgiaFellowship, Hematology and Medical Oncology, 2005 - 2006
ECU Health Medical Center/East Carolina UniversityResidency, Internal Medicine, 2002 - 2005- Medical College of GeorgiaFellowship, Hematology and Medical Oncology, 2000 - 2002
Ankara University FOMClass of 1990
Certifications & Licensure
IL State Medical License 2018 - 2026
IN State Medical License 2023 - 2023
MN State Medical License 2010 - 2019
GA State Medical License 2005 - 2011
NC State Medical License 2002 - 2006- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT Start of enrollment: 2017 Apr 12
Publications & Presentations
PubMed
- 8 citationsOutcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow...Hemant S Murthy, Kwang Woo Ahn, Noel Estrada-Merly, Hassan B Alkhateeb, Susan Bal
Transplantation and Cellular Therapy. 2022-04-01 - 718 citationsGilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AMLAlexander E. Perl, Giovanni Martinelli, Jorge E. Cortes, Andreas Neubauer, Ellin Berman
The New England Journal of Medicine. 2019-10-30 - 355 citationsSelective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 studyAlexander E. Perl, Jessica K. Altman, Jorge E. Cortes, Catherine C. Smith, Mark R. Litzow
The Lancet. Oncology. 2017-08-01
Journal Articles
- Diffuse Alveolar Hemorrhage Is Most Often Fatal and Is Affected by Graft Source, Conditioning Regiment Toxicity, and Engraftment KineticsErhan H Dincer, Erica D Warlick, Margaret L MacMillan, Patrick Arndt, Daniel J Weisdorf, Nelli Bejanyan, Claudio G Brunstein, Celalettin Ustun, Aleksandr Lazaryan, Ver..., Haematologica
Lectures
- Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Higher Stakes in Systemic MastocytosisJune 18th, 2021
Nonmyeloablative Conditioning Carries Lowers Infection Risk in Patients with AMLSeptember 10th, 2019
Insurance Accepted
- Aetna Choice POS II
Anthem HealthKeepers HMO/POS
Anthem KeyCare PPO
BCBS Blue Card PPO
BCBS Georgia Blue Choice HMO
BCBS Georgia BlueChoice Option POS
BCBS Illinois PPO
BCBS Minnesota Blue Cross Accord
CIGNA Open AccessCIGNA PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
